HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 5, 2004, Pages 700-701

  Doggen, C J M ^a,b   Lemaitre, R N ^a   Smith, N L ^a   Heckbert, S R ^a   Psaty, B M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; ESTROGEN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BODY HEIGHT; BODY WEIGHT; CASE CONTROL STUDY; CLINICAL TRIAL; COMPUTER SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER ECHOGRAPHY; DRUG DOSE REGIMEN; DRUG USE; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG ANGIOGRAPHY; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MEDICAL RECORD; PATIENT COMPLIANCE; PHLEBOGRAPHY; POPULATION RESEARCH; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES; VEIN THROMBOSIS; VENA CAVA FILTER;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; POSTMENOPAUSE; PRAVASTATIN; RISK; SIMVASTATIN; VENOUS THROMBOSIS;

EID: 4744342682     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00696.x     Document Type: Article

References (7)

1. Ray JG. Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med 2003; 9: 378-84.
2. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Arch Intern Med 2000; 132: 689-96.
3. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161: 1405-10.
4. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic: and pharmacokinetic; properties of statins. Pharmacol Therapeutics 1999; 84: 413-28.
5. Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285: 906-13.
6. Colli S, Eligini S, Lalli M, Camera M, Paolett R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. Arterioscler Thromb Vasc Biol 1997; 17: 265-72.
7. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va initiation. Circulation 2001; 103: 2248-53.